EchoStar Corp

SATS remains in a Stage 4 decline with confirmed lower highs/lows and a decisive support failure. Medium-term asymmetry is firmly bearish, but price is extended below the 9-day and 21-day EMAs and the 50-day SMA at extreme oversold levels, increasing bounce risk. Selling deeper into this extension is ill‐timed, so we recommend trimming on rallies back into resistance around the EMAs and 50-day SMA.

• ↑Q4 2025 revenue $1.4 B (+2% YoY) supports core stability.
• ↑OIBDA rose 5% YoY to $250 M, highlighting cost management.
• ↓Total debt $3 B and operating expenses +8% YoY squeeze profits.